GLP1R and Parkinson disease: Interestingly, they reported an important inverse association between use of DPP4 inhibitors and GLP-1 agonists and the onset of PD, with an adjusted incidence rate ratio of 0.64 (95% CI, 0.43–0.88; p < 0.01) for DPP-4 inhibitors [4].